Versant Venture Management is an investment fund managing more than $77.3 billion ran by Max Eisenberg. There are currently 8 companies in Mr. Eisenberg’s portfolio. The largest investments include CRISPR Therapeutics AG and Contineum Therapeutics, Inc., together worth $43.1 billion.
As of 31st July 2024, Versant Venture Management’s top holding is 498,558 shares of CRISPR Therapeutics AG currently worth over $26.9 billion and making up 34.8% of the portfolio value.
Relative to the number of outstanding shares of CRISPR Therapeutics AG, Versant Venture Management owns more than approximately 0.1% of the company.
In addition, the fund holds 918,163 shares of Contineum Therapeutics, Inc. worth $16.2 billion.
The third-largest holding is Skye Bioscience, Inc. worth $16.1 billion and the next is Repare Therapeutics worth $8.73 billion, with 2,646,657 shares owned.
Currently, Versant Venture Management's portfolio is worth at least $77.3 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Versant Venture Management office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Max Eisenberg serves as the Chief Operating Officer at Versant Venture Management.
In the most recent 13F filing, Versant Venture Management revealed that it had opened a new position in
Contineum Therapeutics, Inc. and bought 918,163 shares worth $16.2 billion.
On the other hand, there are companies that Versant Venture Management is getting rid of from its portfolio.
Versant Venture Management closed its position in Rayzebio, Inc. on 7th August 2024.
It sold the previously owned 5,158,161 shares for $115 billion.
Max Eisenberg also disclosed a decreased stake in Adverum Biotechnologies Inc by 0.9%.
This leaves the value of the investment at $3.48 billion and 506,821 shares.
The two most similar investment funds to Versant Venture Management are Oxford Asset Management LL.P. and H Capital V Gp, L.P.. They manage $77.5 billion and $77.5 billion respectively.
Versant Venture Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 55.4% of
the total portfolio value.
The fund focuses on investments in the Switzerland as
12.5% of the portfolio companies
are based in the Switzerland.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
38% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $944 million.
These positions were updated on August 7th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Rayzebio, Inc. |
Closed
5,158,161
|
$114,511,174,000 | |
| CRISPR Therapeutics AG |
No change
498,558
|
$26,927,118,000 | 34.84% |
| Contineum Therapeutics, Inc. |
Opened
918,163
|
$16,168,850,000 | 20.92% |
| Skye Bioscience, Inc. |
Opened
2,007,704
|
$16,081,709,000 | 20.81% |
| Repare Therapeutics Inc. |
No change
2,646,657
|
$8,733,968,000 | 11.30% |
| Adverum Biotechnologies Inc |
90.00%
506,821
|
$3,476,792,000 | 4.50% |
| Passage Bio Inc |
18.82%
4,026,417
|
$3,197,780,000 | 4.14% |
| Gritstone Oncology, Inc. |
No change
3,561,150
|
$2,200,435,000 | 2.85% |
| Aligos Therapeutics, Inc. |
37.17%
1,457,937
|
$510,278,000 | 0.66% |
| Minerva Surgical Inc. |
Closed
83,684
|
$275,320,000 | |
| No transactions found | |||
| Showing first 500 out of 10 holdings | |||